Results 91 to 100 of about 3,650 (207)

Body Composition And Weight Gain In New Users Of The Three-monthly Injectable Contraceptive, Depot-medroxyprogesterone Acetate, After 12 Months Of Follow-up

, 2015
Objectives: To evaluate weight gain and body composition (BC) in new users of depot-medroxyprogesterone acetate (DMPA) as a contraceptive. Methods: This cohort study followed up 20 DMPA users and 20 copper intrauterine device (TCu380A IUD) users, paired ...
Pavin E.J., Dal'Ava N., Fernandes A.M.D.S., Bahamondes M.V., Modesto W.O., Dos Santos P.D.N.S.   +5 more
core   +1 more source

Membranous Dysmenorrhea: A Case Series

The Scientific World Journal, 2007
The purpose was to illustrate the variability of hormonal contraception of patients that presented with membranous dysmenorrheal. A case analysis chart review was completed on six patients referred to a Pediatric Gynecologist in an academic setting.
Hatim A. Omar, Shawn J. Smith
doaj   +1 more source

Exploring the Reasons for Dropouts of Injectable Contraceptive in Burdwan Municipal area, West Bengal, India: Beneficiaries’ and Service Providers’ Perspectives

Current Medical Issues
Introduction: The inclusion of the Injectable Contraceptive, Antara Programme into family planning services signals a shift in the nation’s perspective and helps recipients achieve their goals for reproductive health.
Arif Hossain, Pramit Goswami, Kaushik Mitra, Pranita Taraphdar, Suman Sannigrahi, Soumik Dandapat   +5 more
doaj   +1 more source

Depot medroxyprogesterone acetate versus norethisterone oenanthate for long-acting progestogenic contraception : a systematic review

, 2006
Includes bibliographical references.[Background] Two injectable progestogen-only contraceptives (IPCs) depot medroxyprogesterone acetate (DMPA) and norethisterone oenanthate (NET-EN) continue to be extensively used in some countries, forming a large ...
Draper, Beverly
core  

Effect of depot medroxyprogesterone acetate and testosterone oenanthate on serum lipoproteins in man

, 1990
Ten normal men were given three monthly intramuscular injections of 200mg of depot medroxyprogesterone acetate (DMPA) and 250mg of testosterone oenanthate (TE) as part of a male contraceptive trial.
Wallace, E M, Wu, F C
core   +1 more source

Pharmacodynamic effects of depot-medroxyprogesterone acetate (DMPA) administered to lactating women on their male infants

, 1996
Normal postpartum women, who had a spontaneous vaginal delivery of one full-term male infant, free of congenital abnormalities and other diseases, were recruited for this study.
Wolthers, BG, Vichaidith, P, Virutamasen, P, Leepipatpaiboon, S, Muia, PN, SekaddeKigondu, CB, Mati, JKG, Forest, MG, dArcangues, C, Kriengsinyot, R, Dikkeschei, LD   +10 more
core   +2 more sources

Depot-medroxyprogesterone acetate: Lipid profile changes and associated cardiovascular risks among acceptors in Sagamu, South West Nigeria. [PDF]

J Public Health Afr, 2023
Odelola O, Akadri A.
europepmc   +1 more source

Breast Cancer and Depot-Medroxyprogesterone Acetate [PDF]

Obstetrical & Gynecological Survey, 1992
DAVID B. THOMAS, ELIZABETH A. NOONAN
openaire   +1 more source

Depot-medroxyprogesterone acetate use and the concentration of Gardnerella vaginalis in vaginal secretions: A cross-sectional study

, 2018
Thesis (Master's)--University of Washington, 2018Studies have observed an association between depot-medroxyprogesterone acetate (DMPA) use and bacterial vaginosis (BV).
Milne-Price, Ryann
core  

A randomized crossover study to evaluate local tolerability following subcutaneous administration of a new depot medroxyprogesterone acetate contraceptive formulation. [PDF]

Contracept X, 2023
Halpern V, Wheeless A, Brache V, Lendvay A, Cochón L, Taylor D, Dorflinger LJ.   +6 more
europepmc   +1 more source